Type 1 diabetes reversed by new cell transplantation technique

Original Article ↗ Hacker News Discussion ↗

Study scope and limitations

  • Multiple commenters stress this result is only in mice, often in specially engineered “T1D-like” models.
  • Some see it as incremental but not “general-public newsworthy” yet; others argue any successful reversal, even in animals, is meaningful progress.
  • Several ask for the article title to clearly state it’s a mouse study to avoid misleading hype.

Immunosuppression trade-offs

  • Long-term immunosuppressants are widely described as a worse quality of life than insulin, which is why pancreas transplants are rare in T1D.
  • Many T1D commenters say they would not trade current insulin therapy for lifelong immune suppression unless side effects were dramatically reduced.
  • Consensus: techniques that still require broad immunosuppression are unlikely to be true breakthroughs.

Autoimmunity and immune engineering

  • Core challenge: T1D is autoimmune; replacing β-cells (even from the patient’s own stem cells) may just invite another attack.
  • Ideas discussed:
    • “Caging” or shielding cells (analogous to blood-brain barrier/placenta).
    • Genetically engineered hypoimmune islet cells and immune-evasive vascular scaffolds.
    • Insulin-specific or antigen-specific immunotherapies to restore tolerance without global suppression.
    • Extreme “immune system reboot” approaches (bone marrow–like) already tried in small numbers, but seen as too risky for most T1D.

Alternative and complementary approaches

  • Closed-loop “artificial pancreas” systems:
    • Some see them as the most realistic near-term improvement.
    • Others criticize them as only marginally better than injections, with device burden, slow insulin kinetics, and CGM limitations.
  • Diet/fasting:
    • Anecdotes of temporary T1D “quasi-remission” or better control after prolonged fasting, severe illness, or ultrarunning.
    • Thread notes related mouse diet studies; whether these are true remissions in humans is unclear.

Cancer risk and specific drugs

  • Concern that standard immunosuppression increases cancer risk, making the trade-off with T1D unattractive.
  • Counterpoint: rapamycin/everolimus may reduce cancer incidence in some transplant cohorts and are also used as cancer therapies.
  • Others note cancers can develop drug resistance; debate remains unresolved in the thread.

Public funding and political context

  • The work is linked to NIH funding; several lament current and proposed cuts to NIH and related agencies.
  • Debate over whether “slashing” budgets is efficient optimization or destructive loss of scientific capacity and institutional knowledge.
  • Some argue basic research needs stable public funding because it’s impossible to know in advance which projects will pay off.